Physician profile
Tara Drinnon
NPI 1659042000
$2,495.81
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.21 · 2022: $753 · 2023: $1,040 · 2024: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.12 | 2021-2024 | |
| Lilly USA, LLC | $320.72 | 2022-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $171.20 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.27 | 2022-2024 | Synjardy, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $159.20 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Lexicon Pharmaceuticals, INC. | $122.06 | 2024 | Inpefa |
| Pfizer INC. | $119.69 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.75 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $113.56 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $86.68 | 2022 | |
| Astellas Pharma US INC | $80.03 | 2023 | Veozah |
| Amgen INC. | $74.60 | 2022-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $64.67 | 2022-2024 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $42.95 | 2023-2024 | Rexulti |
| Dexcom, INC. | $34.24 | 2022-2024 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.72 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $25.46 | 2022 | |
| Merck Sharp & Dohme LLC | $24.56 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $21.78 | 2024 | Givlaari |
| Xeris Pharmaceuticals, INC. | $19.86 | 2023 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $17.64 | 2023 | Nuzyra |
| Amarin Pharma, INC. | $17.61 | 2022 | |
| Inogen, INC. | $17.24 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.72 | 2021 | |
| Neurocrine Biosciences, INC. | $14.53 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.82 | 2021 | |
| Grt US Holding, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Drinnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.